Recommendations for the Treatment of Children With Burkitt's Lymphoma

Sponsor
French Africa Pediatric Oncology Group
Study ID
NCT04425421
Status
Recruiting
Apply to this trial

Conditions

  • Burkitt Lymphoma

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • OBSERVATIONAL — OTHER
    OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE

Study Details

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Key Dates

First listed
Jun 11, 2020
Start date
Nov 1, 2020
Status verified
Feb 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2030

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: All children with Burkitt lymphoma and in 2 units the addition of Rituximab
    An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations "GFA LMB2019" which are the basis, the other centers will continue with this GFALMB2019 protocol as is

Primary Outcome Measure

Evaluation of the number of cases with local disease. [ Time Frame: 5 years ]

Central Contacts

Related Studies